{
    "2020-04-03": [
        [
            {
                "time": "2020-03-15",
                "original_text": "Wilmington-based Incyte looking to repurpose flagship drug as COVID-19 treatment",
                "features": {
                    "keywords": [
                        "Incyte",
                        "repurpose",
                        "flagship drug",
                        "COVID-19"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-03-16",
                "original_text": "Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Coronavirus",
                        "Amgen",
                        "Incyte"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-03-17",
                "original_text": "Novartis Enlists Bone Marrow Cancer Drug in Fight Against Covid-19",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Bone Marrow",
                        "Cancer Drug",
                        "Covid-19"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-03-18",
                "original_text": "A Cancer Drug From Incyte and Novartis Is Latest Potential Weapon Against Covid-19",
                "features": {
                    "keywords": [
                        "Cancer Drug",
                        "Incyte",
                        "Novartis",
                        "Covid-19"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-03-19",
                "original_text": "The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO",
                "features": {
                    "keywords": [
                        "Biotech",
                        "Fate Therapeutics",
                        "Cell Therapy",
                        "J&J",
                        "Zentalis IPO"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-03-20",
                "original_text": "Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Incyte",
                        "repurposing",
                        "Jakavi",
                        "COVID-19"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}